Corrections
Correction, 27 September 2026: an earlier version of this story misstated the size of the funding round. It has been corrected.
Merck secures first approval for an oral PCSK9 inhibitor, reshaping the cholesterol market
Lipfendra clears the FDA as the first oral entrant in a class previously limited to injectables, with a NICE appraisal pending.

The United States Food and Drug Administration (FDA) has granted its approval to Lipfendra, a groundbreaking oral PCSK9 inhibitor developed by pharmaceutical giant Merck. This landmark decision marks a significant turning point in the management of hypercholesterolemia, as it introduces the first orally administered compound in a therapeutic class that has, until now, exclusively comprised injectable medications requiring administration on a fortnightly or monthly basis. The move is widely anticipated to redefine patient access and compliance in a crucial area of cardiovascular health.
This regulatory endorsement by the FDA is expected to generate considerable interest across other major healthcare markets, including the United Kingdom. While the precise pricing strategy for Lipfendra in the UK has not yet been formally disclosed by Merck, anticipation is building ahead of its appraisal by the National Institute for Health and Care Excellence (NICE). The outcome of this appraisal, particularly how the committee evaluates Lipfendra against the established injectable PCSK9 inhibitors, will be pivotal in determining the speed and extent of its integration into primary care settings within the National Health Service (NHS).
Premium story
Create a free account for 3 premium articles a month
Free members read three premium pieces every month. Or go unlimited with Premium.
Create a free accountPremium
£29/month or £290/year
Unlimited premium analysis, The Analyst Note and the full archive.
Choose PremiumAlready a member? Sign in
Source: Financial Times
Related stories

Healthcare Technology
Abridge raises $340m Series D to scale ambient AI across US health systems

Healthcare Technology
FDA extends Casgevy approval to children aged two and over, raising payer coverage questions

Healthcare Technology
Paige raises $75m Series C to widen digital pathology footprint in Europe